arrow
E

Elena Fountzilas

st luke's clinic
H指数:24
被引数:3,091

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Integrated Molecular, Clinicopathological and Immune Profiling of Non-Small Cell Lung Cancer: The MONREPOS Hellenic Cooperative Oncology Group (HeCOG) Study (HE_2TR/13)

非小细胞肺癌的整合分子、临床病理和免疫特征分析:MONREPOS 希腊合作肿瘤学组 (HeCOG) 研究 (HE_2TR/13)

2026-09-300
OA
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

可解释AI决策支持工具的临床可用性及非小细胞肺癌中多模态模型的评估

2026-09-130
OAAI
Characteristics and Clinical Outcomes of BRCA Germline Mutation Carriers with Advanced Breast Cancer Treated with PARP (Poly ADP-Ribose Polymerase) Inhibitors: A Single-Institution Experience

BRCA生殖系突变携带者晚期乳腺癌接受PARP(聚腺苷二磷酸核糖聚合酶)抑制剂治疗的特征与临床结局:单机构经验

Cancers
IF4.4
2026-04-170
OA
An observational retro-prospective study on patients with head and neck cancer who contracted COVID-19 (HERODOTUS: head and neck cancERs international cOviD-19 collabOraTion)

头颈癌合并COVID-19患者的观察性回顾-前瞻性研究(HERODOTUS:头颈癌国际COVID-19协作研究)

2026-04-010
PRE
Understanding Exceptional Response: The Role of MINDY1 SNP in CDK4/6 Inhibitor Therapy for ER-Positive, HER2-Negative Advanced Breast Cancer

理解超常反应:MINDY1 SNP在ER阳性、HER2阴性晚期乳腺癌CDK4/6抑制剂疗法中的作用

2025-12-240
OAAI
Evaluation of the 1021-HRD assay compared to established HRD testing platforms in ovarian cancer

与已建立的HRD检测平台相比,1021-HRD检测在卵巢癌中的评估

2025-11-290
OAAI
Intercalated Avelumab plus platinum-based chemotherapy in patients with Extensive-Stage Small-Cell Lung cancer (PAVE): Final Outcome, Immunophenotypic and biomarker analysis of a multi-center phase II Hellenic Cooperative Oncology Group study.

插入式阿维鲁唑胺联合铂类为基础的化疗在广泛期小细胞肺癌患者中的应用(PAVE):一项多中心Hellenic Cooperative Oncology Group II期研究的最终结果、免疫表型分析和生物标志物分析。

2025-07-250
OAAI
Genomic risk assessment with Oncotype DX in young women (age ≤ 40 years old) with early-stage ER+/HER2-/N0 breast cancer

使用Oncotype DX对年龄≤40岁的早期ER+/HER2-/N0乳腺癌女性进行基因组风险评估

BREAST
IF7.9
2025-02-010
OAAI
Polygenic Risk Score (PRS) Combined with NGS Panel Testing Increases Accuracy in Hereditary Breast Cancer Risk Estimation

多基因风险评分 (PRS) 与NGS小组测试相结合,可提高遗传性乳腺癌风险评估的准确性

2024-08-210
OAAI
Nationwide Real-World Data of Microsatellite Instability and/or Mismatch Repair Deficiency in Cancer: Prevalence and Testing Patterns

癌症中微卫星不稳定性和/或错配修复缺陷的全国真实数据: 患病率和测试模式

2024-05-222
OAAI
Real-world data on the safety and efficacy of trastuzumab deruxtecan and sacituzumab govitecan in patients with advanced breast cancer: the experience of the Hellenic Cooperative Oncology Group
2024-03-010
PRE
Clinical and molecular study with digital support of advanced non-small cell lung cancer patients: SNF-CLIMEDIN, a prospective randomized Hellenic Cooperative Oncology Group (HeCOG) study: Interim analysis

晚期非小细胞肺癌患者数字支持的临床和分子研究: snf-climedin,一项前瞻性随机希腊肿瘤协作组 (HeCOG) 研究: 中期分析

2023-10-011
OAAI
The Utility of NGS Analysis in Homologous Recombination Deficiency Tracking
2023-09-152
OAAI